FOUNDATIONONE®CDx

PATIENT

TUMOR TYPE
Lung adenocarcinoma

REPORT DATE

COUNTRY CODE
IT

ORDERED TEST #

Rapport remis à titre d'exemple, valide en date du 14/03/2022

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT	PHYSICIAN	SPECIMEN
DISEASE Lung adenocarcinoma	ORDERING PHYSICIAN	SPECIMEN SITE
NAME	MEDICAL FACILITY	SPECIMEN ID
DATE OF BIRTH	ADDITIONAL RECIPIENT	SPECIMEN TYPE
SEX	MEDICAL FACILITY ID	DATE OF COLLECTION
MEDICAL RECORD #	PATHOLOGIST	SPECIMEN RECEIVED

Genomic Signatures

Microsatellite status - MS-Stable
Tumor Mutational Burden - 8 Muts/Mb

Gene Alterations

For a complete list of the genes assayed, please refer to the Appendix.

EGFR exon 19 deletion (T751_I759>N)
CCND1 amplification
CDK4 amplification - equivocal†
FGF19 amplification - equivocal†
FGF3 amplification - equivocal†
FGF4 amplification - equivocal†
KDM6A rearrangement intron 10, rearrangement exon 23
NFKBIA amplification - equivocal†
NKX2-1 amplification - equivocal†
TP53 C176Y

7 Disease relevant genes with no reportable alterations: ***ALK, BRAF, ERBB2, KRAS, MET, RET, ROS1***

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Afatinib** (p. 9), **Dacomitinib** (p. 10), **Erlotinib** (p. 10), **Gefitinib** (p. 11), **Osimertinib** (p. 12)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 13)

GENOMIC SIGNATURES	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Genomic Signatures section
Tumor Mutational Burden - 8 Muts/Mb	**No therapies or clinical trials.** see Genomic Signatures section

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE ALTERATIONS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
EGFR - exon 19 deletion (T751_I759>N)	Afatinib 1	none
	Dacomitinib 1	
	Erlotinib 1	
	Gefitinib 1	
10 Trials *see p. 17*	Osimertinib 1	
CCND1 - amplification	none	none
9 Trials *see p. 13*		
CDK4 - amplification - equivocal	none	none
10 Trials *see p. 15*		

1 *NCCN category*

GENE ALTERATIONS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Alterations section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved through a centralized EU procedure or a national procedure in an EU Member State. Therapies, including but not limited to the following, have been approved nationally and may not be available in all EU Member States: Tretinoin, Anastrozole, Bicalutamide, Cyproterone, Exemestane, Flutamide, Goserelin, Letrozole, Leuprorelin, Triptorelin.

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENOMIC SIGNATURE

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

MSI-H is generally infrequent in NSCLC, reported in fewer than 1% of samples across several large studies[6-11], whereas data on the reported incidence of MSI-H in SCLC has been limited and conflicting[12-15]. One study reported MSI-H in lung adenocarcinoma patients with smoking history, and 3 of 4 MSI-H patients examined also had metachronous carcinomas in other organs, although this has not been investigated in large scale studies[6]. Published data investigating the prognostic implications of MSI in NSCLC are limited (PubMed, Oct 2021).

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[16]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[16-18]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[19-21]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[16,18,20-21].

GENOMIC SIGNATURE

Tumor Mutational Burden

RESULT
8 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[22-24], anti-PD-1 therapies[22-25], and combination nivolumab and ipilimumab[26-31]. Multiple clinical trials of PD-1- or PD-L1-targeting immune checkpoint inhibitors or combination of PD-1 and CTLA-4 inhibitors in NSCLC have reported that patients with tumors harboring TMB ≥10 Muts/Mb derive greater clinical benefit from these therapies than those with TMB <10 Muts/Mb (based on this assay or others); similarly, higher efficacy of anti-PD-1 or anti-PD-L1 immunotherapy for treatment of patients with NSCLC, compared with the use of chemotherapy, has been observed more significantly in cases of TMB ≥10 Muts/Mb (based on this assay or others);[22-23,26-28,32-39]. Improved OS of patients with NSCLC treated with pembrolizumab plus chemotherapy relative to chemotherapy only[40], or those treated with nivolumab plus ipilimumab also relative to chemotherapy[41], has been observed across all TMB levels.

FREQUENCY & PROGNOSIS

A large-scale genomic analysis found that unspecified lung non-small cell lung carcinoma (NSCLC), lung adenocarcinoma, and lung squamous cell carcinoma (SCC) samples harbored median TMBs between 6.3 and 9 Muts/Mb, and 12% to 17% of cases had an elevated TMB of greater than 20 Muts/Mb[42]. Lower TMB is observed more commonly in NSCLCs harboring known driver mutations (EGFR, ALK, ROS1, or MET) with the exception of BRAF or KRAS mutations, which are commonly observed in elevated TMB cases[43]. Although some studies have reported a lack of association between smoking and mutational burden in NSCLC[44-45], several other large studies did find a strong association with increased TMB[46-49]. TMB >10 muts/Mb was found to be more frequent in NSCLC metastases compared with primary tumors for both adenocarcinoma (38% vs. 25%) and SCC (41% vs. 35%) subtypes[50]. A large study of Chinese patients with lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)[44]. Another study of patients with NSCLC correlated elevated TMB with poorer prognosis and significantly associated lower TMB in combination with PD-L1 negative status with longer median survival in patients with lung adenocarcinoma[51]. However, no significant prognostic association of TMB and/or PD-L1 status with survival has been reported in patients with lung SCC[51-52].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[53-54] and cigarette smoke in lung cancer[32,55], treatment with temozolomide-based chemotherapy in glioma[56-57], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[58-62], and microsatellite instability (MSI)[58,61-62]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[22-23,26-28,32-39,63].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE
EGFR

ALTERATION
exon 19 deletion (T751_I759>N)

TRANSCRIPT ID
NM_005228

CODING SEQUENCE EFFECT
2252_2276>A

VARIANT ALLELE FREQUENCY (% VAF)
24.6%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

For patients with non-small cell lung cancer, EGFR activating mutations may predict sensitivity to EGFR TKIs, including erlotinib[64], gefitinib[65], afatinib[66], dacomitinib[67], and osimertinib[68]; however, the data for patients with other tumor types are limited[69-74]. The Phase 1 CHRYSALIS study of amivantamab monotherapy or in combination with lazertinib for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) has produced encouraging preliminary results for treatment-naive patients and patients who relapsed after treatment with osimertinib with and without chemotherapy, including osimertinib-relapsed patients with biomarkers indicating EGFR/MET-based osimertinib resistance[75-78] . In a Phase 1 trial, the HER3-targeted antibody patritumab deruxtecan elicited an ORR of 39% (22/57, 1 CR) and a median PFS of 8.2 months for patients with non-small cell lung cancer previously treated with an EGFR TKI, many of whom displayed TKI resistance alterations[79]. A Phase 1 trial evaluating the EGFR inhibitor AZD3759 reported a reduction in the volume of brain metastases in 40% (8/20) of patients with previously treated non-small cell lung cancer (NSCLC) harboring either the EGFR L858R alteration or EGFR exon 19 deletion, including 3 confirmed PRs and 3 unconfirmed PRs[80-81]. In a Phase 1/2 trial for advanced NSCLC, the brain-penetrant third-generation EGFR TKI lazertinib enabled ORRs of 54% (69/127) for all evaluable patients and 44% (8/18, intracranial) for patients with brain metastases[82]. The Phase 3 IMpower150 study showed that the addition of atezolizumab to bevacizumab plus chemotherapy treatment also had clinical efficacy for patients with EGFR-mutated or ALK-rearranged metastatic NSCLC[83]; therefore, the patient's clinical context should be considered.

FREQUENCY & PROGNOSIS

EGFR mutation has been reported in 12-36% of lung adenocarcinomas[48,84-85] and in 4% of lung squamous cell carcinomas[86]. EGFR protein expression/overexpression has been reported in up to 70% of NSCLC cases[87-92]. In addition, expression of EGFR protein has been shown to be higher in lung squamous cell carcinoma samples as compared to lung adenocarcinoma[93-94]. In patients with lung adenocarcinoma, EGFR mutation was a predictor of poor overall survival[95-96]. However, EGFR mutations have been reported to predict improved survival in patients with resected Stage 1-3 lung adenocarcinoma[97] or resected Stage 1 NSCLC[98].

FINDING SUMMARY

EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide[99]. EGFR exon 19 deletion mutations, such as seen here, have been shown to activate the tyrosine kinase activity of EGFR and to confer sensitivity to EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib[100-102], afatinib[103], osimertinib[104], and dacomitinib[67,105], although limited preclinical data suggest reduced sensitivity to lapatinib[106-107].

GENE
CCND1

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Amplification or overexpression of CCND1 may predict sensitivity to CDK4/6 inhibitors, such as abemaciclib, palbociclib, and ribociclib[108-113], although as monotherapy these agents have shown limited activity in tumor types other than breast cancer[112,114]. In refractory advanced solid tumors with CCND1 (n=39) or CCND3 (n=1) amplification and retinoblastoma protein expression, palbociclib resulted in SD for 39% (14/36) of patients and a median PFS of 1.8 months in the NCI-MATCH trial[115]; 4 patients (13%, 4/36 overall) with squamous cell carcinomas (lung, esophageal, or laryngeal) or adenoid cystic carcinoma experienced prolonged SD in this study[115]. Among 9 patients with CCND1-amplified advanced solid tumors, 1 patient with bladder cancer responded to ribociclib in a Phase 2 trial[116].

— Potential Resistance —

CCND1 amplification may predict worse outcomes on immune checkpoint inhibitors (anti-PD-1/PD-L1/CTLA-4) in solid tumors on the basis of 2 meta-analyses[117-118]; in these studies, CCND1 amplification was associated with significantly decreased response rate[118] and OS (HR=1.6-2.0)[117-118] across various tumor types and significantly shorter OS specifically in urothelial carcinoma (HR=2.2-3.6), melanoma (HR=1.6-2.5), and solid tumors harboring elevated TMB (HR=2.8)[117-118].

FREQUENCY & PROGNOSIS

CCND1 amplification has been reported in 2-25% of lung adenocarcinoma[48,85,119-120] and 6-38% of lung squamous cell carcinoma[86,119-120] cases. Expression of cyclin D1 has been reported in 59% (36/61) of non-small cell lung cancer (NSCLC) tumors analyzed[121]. The prognostic significance of CCND1 amplification in NSCLC is not clear[122]. Cyclin D1 protein expression was not associated with clinicopathologic parameters of NSCLC in one study[121].

FINDING SUMMARY

CCND1 encodes cyclin D1, a binding partner of the kinases CDK4 and CDK6, that regulates RB activity and cell cycle progression. Amplification of CCND1 has been positively correlated with cyclin D1 overexpression[123] and may lead to excessive proliferation[124-125].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE
CDK4

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

CDK4 amplification or activation may predict sensitivity to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib[109,111-112,126]. Clinical benefit has been reported for limited tumor types including patients with CDK4-amplified liposarcoma and sarcoma in response to treatment with abemaciclib[127], palbociclib[126,128], and ribociclib[116].

FREQUENCY & PROGNOSIS

In the TCGA datasets, CDK4 amplification or mutation occurs in 7% and 1% of lung adenocarcinoma cases, respectively[129]; however, neither were detected in any of the lung squamous cell carcinoma cases[86]. CDK4 amplification correlated with high CDK4 gene and protein expression in lung tumors[130]. High CDK4 protein expression has been detected in 23-47% of non-small cell lung cancers, specifically in 38% (18/47) of lung adenocarcinomas, 44% (4/9) of lung squamous cell carcinomas, and 83% (10/12) of large cell lung cancers[130-132]. A preclinical study suggests targeting of CDK4 as a potential strategy against KRAS-driven lung adenocarcinomas[133]. High CDK4 protein expression predicted poor overall survival in patients with lung cancer in one study[132].

FINDING SUMMARY

CDK4 encodes the cyclin-dependent kinase 4, which regulates the cell cycle, senescence, and apoptosis[134]. CDK4 and its functional homolog CDK6 are activated by D-type cyclins and promote cell cycle progression by inactivating the tumor suppressor Rb[135-136]. Amplification of the chromosomal region that includes CDK4 has been reported in multiple cancer types, including lung cancer, glioblastoma, and liposarcoma, and has been associated with overexpression of CDK4 protein[126,130,137-142].

GENE
FGF19

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies that directly address genomic alterations in FGF19. However, FGF19 amplification predicts sensitivity to FGFR4 inhibitors in liver cancer cell lines[143-144]; selective FGFR4 inhibition reduced tumor burden in an FGF19-amplified HCC xenograft model[145]. A Phase 1 study of the FGFR4 inhibitor fisogatinib (BLU-554) for patients with previously treated hepatocellular carcinoma (HCC), most of whom had received prior sorafenib treatment, reported a 16.7% ORR (11/66, 1 CR, ongoing for >1.5 years) and a median PFS of 3.3 months for FGF19-IHC-positive patients; poorer outcomes (0% ORR, PFS of 2.3 months) were observed for patients with negative or unknown FGF19 IHC scores[146]. Acquisition of FGFR4 mutations may represent a mechanism of resistance for patients with FGF19 overexpression who initially responded but then progressed on fisogatinib[144]. Preliminary results from the dose escalation part of a Phase 1/2 study evaluating another FGFR4 inhibitor, FGF401, showed an ORR of 7.6% (4/53), SD rate of 52.8% (28/53), and a median time to progression of 4.1 months; responses were observed in both FGF19-positive and FGF19-negative cases[147]. In a retrospective analysis, a trend toward response to sorafenib treatment and FGF19 copy number gain was observed in patients with HCC, and 2 patients harboring FGF19 copy number gain experienced a CR[148]. A case study reported activity of pan-FGFR inhibitors in FGF-amplified cancers; following treatment with a selective pan-FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR[149]. Other therapies targeting FGF19 or FGFR4 signaling are in development[150].

FREQUENCY & PROGNOSIS

In the TCGA datasets, FGF19 amplification has been reported with highest incidence in esophageal carcinoma (34%), head and neck squamous cell carcinoma (23%), breast carcinoma (15%), lung squamous cell carcinoma (13%), and cholangiocarcinoma (11%) (cBioPortal, 2021)[151-152]. In HCC, FGF19 is an important driver gene[145,153-154], and FGF19 protein expression correlates with tumor progression and poorer prognosis[155]. Exogenous FGF19 has been shown to promote prostate cancer tumorigenesis in a preclinical study[156], and the presence of FGF19-positive tissues is an independent factor for worse prognosis following radical prostatectomy[157].

FINDING SUMMARY

FGF19 encodes fibroblast growth factor 19, an FGFR4 ligand involved with bile acid synthesis and hepatocyte proliferation in the liver[145,158]. FGF19 lies in a region of chromosome 11q13 frequently amplified in a diverse range of malignancies that also contains FGF3, FGF4, and CCND1[159]. Correlation between FGF19 amplification and protein expression has been demonstrated in hepatocellular carcinoma (HCC)[160] but was not observed in several other tumor types[154].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE
FGF3

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies that directly address genomic alterations in FGF3. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan-FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan-FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR[161].

FREQUENCY & PROGNOSIS

FGF3 lies in a region of chromosome 11q13 that also contains FGF19, FGF4, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. This chromosomal region is frequently amplified in a diverse range of malignancies[124].

FINDING SUMMARY

FGF3 encodes fibroblast growth factor 3, a growth factor that plays a central role in development of the inner ear. Germline mutations in FGF3 give rise to an autosomal recessive syndrome characterized by microdontia, deafness, and complete lack of inner ear structures[162].

GENE
FGF4

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

FGF4 amplification and overexpression was associated with cell sensitivity to the multikinase inhibitor sorafenib in preclinical studies[163-164] and amplification of FGF4/FGF3 in HCC significantly correlated with patient response to sorafenib (p=0.006)[163]. Limited data suggest that pan-FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan-FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR[161].

FREQUENCY & PROGNOSIS

FGF4 lies in a region of chromosome 11q13 that also contains FGF19, FGF3, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. This chromosomal region is frequently amplified in a diverse range of malignancies[124] including esophageal carcinoma (35%), head and neck squamous cell carcinoma (HNSCC; 24%), breast invasive carcinoma (14%), lung squamous cell carcinoma (13%), cholangiocarcinoma (11%), bladder urothelial carcinoma (10%), stomach adenocarcinoma (7%), skin melanoma (5%), and hepatocellular carcinoma (HCC; 5%), however FGF4 amplification is rare in hematopoietic and lymphoid malignancies, reported in less than 1% of samples analyzed (cBioPortal, 2021)[151-152].

FINDING SUMMARY

FGF4 encodes fibroblast growth factor 4, which plays a central role in development of the teeth[165] and acts synergistically with other FGFs and SHH (sonic hedgehog) to regulate limb outgrowth in vertebrate development[166]. FGF4 lies in a region of chromosome 11q13 that also contains FGF19, FGF3, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. Amplification of FGF4, along with that of FGF3, FGF19, and CCND1, has been reported in a variety of cancers[124,163,167-170] and may confer sensitivity to the multi-kinase inhibitor sorafenib[163].

GENE
KDM6A

ALTERATION
rearrangement intron 10, rearrangement exon 23

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies available to address KDM6A alterations in cancer.

FREQUENCY & PROGNOSIS

KDM6A mutations have been reported in 3.9% of samples analyzed, with the highest incidence in tumors of the urinary tract (31%), endometrium (7%), and salivary gland (6%) (COSMIC, 2021)[171]. KDM6A mutations or copy number alterations have also been identified in medulloblastoma (8.9%)[172], adenoid cystic carcinoma (6.7%)[173], and metastatic prostate cancer (10%)[174]. KDM6A inactivation has been found as a recurrent tumorigenic event in male T-cell acute lymphoblastic leukemia (T-ALL), and loss of KDM6A increased the sensitivity of T-ALL cells to therapies targeting histone H3 lysine 27 methylation in preclinical assays[175]. However, KDM6A overexpression has been noted in breast cancer and renal cell carcinoma, and correlated with inferior prognosis in patients with breast cancer[176-178].

FINDING SUMMARY

KDM6A encodes a histone H3 lysine 27 demethylase UTX, which functions as a transcriptional regulator[179]. A significant number of inactivating KDM6A mutations have been found across multiple tumor types, suggesting a role as a tumor suppressor[179].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE
NFKBIA

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies that directly target NFKBIA amplification or expression.

FREQUENCY & PROGNOSIS

In the TCGA datasets, amplification of NFKBIA has been reported with the highest incidence in lung adenocarcinoma (11.7%)[85], esophageal carcinoma (3.8%), prostate adenocarcinoma (3.4%)[180], lung squamous cell carcinoma (2.8%)[86], and ovarian serous cystadenocarcinoma (2.6%) (cBioPortal, 2021)[151-152]. Amplification or increased expression of NFKBIA in EGFR-mutant lung cancer has been reported to predict improved response to EGFR tyrosine kinase inhibitors[181-182]. Certain NFKBIA polymorphisms, which may affect IkBa expression levels, have been studied as risk factors for some cancer types, although the data are mixed and conflicting[183-185].

FINDING SUMMARY

NFKBIA encodes IkBa, an inhibitor of the NF-kappaB (NFkB)/REL complex. It has been reported to act as a tumor suppressor in Hodgkin's lymphoma[186-190] and in glioblastoma[183,191-192]. NFKBIA has been reported to be amplified in cancer[152] and may be biologically relevant in this context[193-194]. In contrast, truncating mutations that result in loss of the majority of the IkBa protein are predicted to be inactivating.

GENE
NKX2-1

ALTERATION
amplification - equivocal

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies or trials that target tumors with TTF-1 amplification or overexpression. Lung cancer cell lines that express both TTF-1 and NKX2-8, which is located in the same amplicon as NKX2-1, have demonstrated resistance to cisplatin therapy[195], although conflicting data has also been reported[196].

FREQUENCY & PROGNOSIS

Putative amplification of NKX2-1 has been reported with the highest incidence in lung cancer, and has been observed in 14% of adenocarcinomas[85] and 5% of squamous cell carcinomas (SCC)[86] as well as other tumor types including prostate adenocarcinomas (6%)[180], and poorly differentiated and anaplastic thyroid cancers (4%)[197]. NKX2-1 mutation has been observed in 9% of acinar cell carcinomas of the pancreas[198], 5% of uterine carcinosarcomas[199], and is infrequent in other tumor types (cBioPortal, COSMIC, 2021)[151-152,171]. TTF-1 is expressed in a majority of lung adenocarcinomas and small cell carcinomas, as well as in a subset of thyroid and CNS tumors[200-202]. Cytoplasmic TTF-1 expression has been reported as an adverse prognostic factor in breast carcinoma[203-204]. However, whether amplification and/or expression status of NKX2-1 have prognostic implications for patients with lung cancer is controversial[195-196,205-208]. TTF-1 has been observed to have tumor-promoting as well as anti-oncogenic roles[209-210].

FINDING SUMMARY

NKX2-1 (NK2 homeobox 1) encodes the thyroid transcription factor TTF-1[211]. Amplification of NKX2-1 results in overexpression of TTF-1 and upregulated transcription of downstream target genes[212].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE
TP53

ALTERATION
C176Y

TRANSCRIPT ID
NM_000546

CODING SEQUENCE EFFECT
527G>A

VARIANT ALLELE FREQUENCY (% VAF)
39.5%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[213-216], or p53 gene therapy and immunotherapeutics such as SGT-53[217-221] and ALT-801[222]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild-type[223]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[224]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[225]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[226]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel[227]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations[228]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[221]. Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53-mutated, but not TP53-wild-type, breast cancer xenotransplant mouse model[229]. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR-246[230-232]. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[233]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[234-235]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[236-237]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

TP53 is one of the most commonly mutated genes in lung cancer; mutations have been reported in 43-80% of non-small cell lung cancers (NSCLCs)[85-86,238-243], including 42-52% of lung adenocarcinomas and 58-83% of lung squamous cell carcinomas (cBioPortal, COSMIC, Feb 2021)[48-49,85-86]. TP53 homozygous deletion has been observed in 1.4% of lung adenocarcinoma and <1% of lung squamous cell carcinoma cases (cBioPortal, Feb 2021)[151-152]. In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD-L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD-1 inhibitors pembrolizumab and nivolumab in this study[244]. Mutations in TP53 have been associated with lymph node metastasis in patients with lung adenocarcinoma[245].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[246]. Alterations such as seen here may disrupt TP53 function or expression[247-251].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2021)[252]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[253-255], including sarcomas[256-257]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[258] to 1:20,000[257]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[259]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[260-265]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[260-261]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[266]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[264,267-268]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

Afatinib

Assay findings association

EGFR
exon 19 deletion (T751_I759>N)

AREAS OF THERAPEUTIC USE

Afatinib is an irreversible kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4. It is available in the EU to treat patients with advanced non-small cell lung cancer (NSCLC) and activating EGFR mutations and for the treatment of patients with advanced squamous NSCLC after progression on platinum-based chemotherapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non-small cell lung cancer[66-67,269-270] , whereas data for patients with other tumor types are limited[69-74,271] .

SUPPORTING DATA

Afatinib has shown significant clinical activity for patients with NSCLC and the EGFR common sensitizing mutations L858R or exon 19 deletions, based on extensive clinical evidence[66,269,272-275] . Two randomized Phase 3 trials reported significantly improved median PFS from afatinib compared with chemotherapy for patients with EGFR common sensitizing mutations (LUX-Lung 3, 13.6 vs. 6.9 months, HR 0.47, p<0.001; LUX-Lung 6, 11.0 vs. 5.6 months, HR 0.28, p<0.0001)[66,269] . However, while afatinib significantly increased OS relative to chemotherapy for patients with EGFR exon 19 alterations in these two trials (LUX-Lung 3, 33.3 vs. 21.1 months, HR=0.54; LUX-Lung 6, 31.4 vs. 18.4 months, HR=0.64), no significant OS differences were observed in treatment for patients with L858R mutation[103]. A similar alteration-specific difference was observed for EGFR-mutated treatment-naive NSCLC in a retrospective analysis, which reported numerically longer median OS from second- versus first-generation EGFR TKIs (48.8 vs. 26.4 months, HR=0.59) for patients with exon 19 deletions, but no substantial difference for patients with L858R (25.4 vs. 20.6 months, HR=0.90)[272]. A Phase 2b study of first-line afatinib compared with gefitinib, also for NSCLC with exon 19 deletions or L858R, reported similar median OS for the two therapies (27.9 vs. 24.5 months, HR=0.86) but significantly longer time-to-treatment-failure (13.7 vs. 11.5 months, HR=0.75) and higher ORR (73% vs. 56%, p=0.0018) with afatinib[273]. Patients with metastatic NSCLC and common EGFR mutations who progressed on prior chemotherapy experienced an ORR of 50.0% (30/60) from afatinib in a Phase 4 trial[274]. As first-line therapy for NSCLC with EGFR exon 19 deletions or L858R, prospective or randomized Phase 2 trials have reported a median PFS of 10.2 months and OS of 24.8 months for patients unfit for chemotherapy[275] and an ORR of 72.5% (n=40, 1 CR), DCR of 100% (40/40), and median PFS and OS of 15.2 and 30.0 months, respectively, for elderly patients ≥70 years old[276]. A retrospective study of afatinib administered to Asian patients with NSCLC, 99% of whom were previously treated with erlotinib and/or gefitinib, reported an ORR of 27.4% (63/230) for patients with common sensitizing EGFR mutations and an ORR of 24.4% (105/431) for the entire cohort[277]. In a case report, a patient with NSCLC with exon 19 deletion and leptomeningeal metastases experienced an ongoing 16-month PR from afatinib in extracranial, brain, and leptomeningeal lesions[278]. For patients with erlotinib- or gefitinib-resistant NSCLC and EGFR mutations, Phase 2/3 studies of afatinib treatment have generally reported ORRs of only 7 to 9%[279-284] ; however, DCRs of more than 50% have been observed[283]. In a Phase 1b or observational study, patients with EGFR-mutated NSCLC who progressed on afatinib experienced further clinical benefit from subsequent treatment with afatinib and cetuximab[285] or osimertinib[286], respectively. Extensive clinical data have demonstrated that afatinib is effective for patients with EGFR-mutated advanced NSCLC, including exon 19 deletions and L858 mutations, as well as uncommon sensitizing mutations in exons 18 or 20[66,103,269,273,275,277,287] . Afatinib has also shown activity for patients with advanced NSCLC and ERBB2 mutations, most of which were exon 20 insertions[283,288-298] . The randomized Phase 3 LUX-Lung 8 trial comparing afatinib with erlotinib as second-line therapy for advanced lung squamous cell carcinoma (SCC) reported significantly longer median OS (7.9 vs. 6.8 months, HR=0.81), significantly longer median PFS (2.6 vs. 1.9 months, HR=0.81), and higher DCR (51% vs. 40%, p=0.002) for patients treated with afatinib[287]. For patients who progressed on afatinib monotherapy, additional clinical benefit has been reported from afatinib combined with paclitaxel[299].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

Dacomitinib

Assay findings association

EGFR
exon 19 deletion (T751_I759>N)

AREAS OF THERAPEUTIC USE

Dacomitinib is a second-generation irreversible tyrosine kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4/HER4. It is available in the EU for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non-small cell lung cancer[66-67,269-270] , whereas data for patients with other tumor types are limited[69-74,271] . Patients with untreated advanced NSCLC and EGFR exon 19 deletions achieved an ORR of 76%[105] and a median OS of 34.1 months with dacomitinib[67].

SUPPORTING DATA

A randomized Phase 3 trial in patients with NSCLC with activating EGFR mutations (primarily L858R or exon 19 deletions) reported improved clinical benefit with first-line dacomitinib compared with gefitinib (median OS, 34.1 vs. 26.8 months, HR=0.760; median PFS, 14.7 vs. 9.2 months, HR=0.59)[105,300] ; median OS was 34.1 to 36.7 months and ORR was 74.9% to 79.3%, depending on the dosing regimen[301]. A pooled subgroup analysis of patients with NSCLC with activating EGFR mutations reported improved clinical efficacy with dacomitinib treatment compared with erlotinib (median PFS, 14.6 vs, 9.6 months, HR=0.717; median OS, 26.6 vs, 23.2 months, HR=0.737)[302]. Reduced efficacy of dacomitinib treatment in patients with NSCLC harboring the EGFR T790M mutation has been reported in multiple studies[303-305] . A Phase 1 trial of combination dacomitinib and a MEK1/2 inhibitor for patients with KRAS-mutated CRC, NSCLC, or pancreatic cancer reported 20/36 SDs and 16 PDs, however toxicity from this combination prevented long-term treatment in this patient population[306]. A Phase 2 study of dacomitinib in patients with NSCLC who had been previously treated with chemotherapy or erlotinib and were not selected for EGFR mutations reported an ORR of 4.5% (3/66)[304]. In one study, the combination of dacomitinib and crizotinib was ineffective and associated with high toxicity in patients with NSCLC[307].

Erlotinib

Assay findings association

EGFR
exon 19 deletion (T751_I759>N)

AREAS OF THERAPEUTIC USE

Erlotinib is an EGFR tyrosine kinase inhibitor. It is available in the EU to treat advanced non-small cell lung cancer (NSCLC) as first-line therapy or switch maintenance therapy for patients with EGFR-activating mutations and as second-line therapy for patients who have progressed on prior chemotherapy. Erlotinib is also available in combination with gemcitabine to treat metastatic pancreatic cancer. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression[64,308-310] .

SUPPORTING DATA

For patients with EGFR-mutated NSCLC, the Phase 3 EURTAC trial reported improved PFS with first-line erlotinib relative to platinum-based chemotherapy (9.7 vs. 5.2 months, HR=0.37)[64]. A Phase 3 study reported similar efficacy of erlotinib and gefitinib for patients with EGFR-mutated NSCLC[311]. Meta-analysis of studies comparing erlotinib or gefitinib versus chemotherapy in the first-line setting reported no significant improvement in OS for patients with EGFR-mutated NSCLC; however, the lack of improved OS was attributed to the effectiveness of postprogression salvage therapy[312]. In the maintenance setting, the placebo-controlled Phase 3 SATURN trial reported significantly improved PFS with maintenance erlotinib following first-line platinum-based chemotherapy irrespective of EGFR status; however, the largest effect was seen for patients with EGFR mutations (HR=0.10)[308]. In the neoadjuvant setting, a Phase 2 trial reported a numerically improved ORR and significantly longer PFS with erlotinib compared with chemotherapy for patients with advanced EGFR-mutated NSCLC[309]. In the placebo-controlled Phase 3 RELAY trial, the addition of ramucirumab to erlotinib improved PFS for previously untreated patients with NSCLC harboring EGFR L858R or exon 19 deletion (19.4 vs. 12.4 months, HR=0.59)[313]. In a Phase 2 trial, no clinical benefit was observed from the addition of bevacizumab to erlotinib for patients with NSCLC harboring EGFR exon 19 deletion or L858R mutation[314]. In one study, median PFS (4.1 vs. 11.7 months, HR=9.7) and median OS (14.1 vs. 47.0 months, HR=10.2) were significantly shorter for patients with NSCLC harboring EGFR L747_A750>P (n=6) relative to those with deletions affecting EGFR E746_A750 (n=24) treated with first-line erlotinib[315]. The Phase 3 BR.21 trial demonstrated prolonged OS for genomically unselected patients with NSCLC treated with erlotinib compared with those treated with standard chemotherapy[316].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

Gefitinib

Assay findings association

EGFR
exon 19 deletion (T751_I759>N)

AREAS OF THERAPEUTIC USE

Gefitinib is an EGFR tyrosine kinase inhibitor available in the EU to treat patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy[310,317-322] , and responses have been reported for patients with EGFR-rearranged NSCLC[323-324] .

SUPPORTING DATA

A Phase 3 trial of first-line gefitinib therapy for patients with NSCLC and EGFR exon 19 deletions or L858R mutations reported a longer PFS (9.2 months vs. 6.3 months)[319] but no change in median OS (34.9 months vs. 37.2 months) compared with patients treated with cisplatin plus docetaxel (median OS of 37.2 months)[325]. Gefitinib achieved an ORR of 69.8% and an OS of 19.2 months as first-line treatment for Caucasian patients with non-small cell lung carcinoma (NSCLC) and EGFR sensitizing mutations[65]. In the retrospective analysis of a Phase 3 study for East Asian patients, gefitinib was reported to have a longer PFS for patients with EGFR mutation-positive NSCLC compared with carboplatin/paclitaxel doublet chemotherapy[320,326] . Two Phase 3 trials of gefitinib plus pemetrexed and carboplatin compared with gefitinib alone for patients with advanced NSCLC harboring EGFR activating mutations reported significantly higher ORRs (75.3% and 84% vs. 62.5% and 67%), longer median PFSs (16 and 20.9 months vs. 8 and 11.9 months), and longer median OSs (50.9 months and not reached vs. 17 and 38.8 months) with combination treatment; however, combination treatment was associated with increased Grade 3 or higher adverse events[327-328] . Retrospective analysis of East Asian patients with advanced NSCLC receiving first-line gefitinib therapy reported that patients with EGFR exon 19 mutations experienced a longer median PFS (10.9 months) compared with patients with EGFR mutations in exon 18 (7.9 months), exon 20 (1.2 months), exon 21 (7.7 months), or double mutations (5.7 months); however, no differences in OS were seen between EGFR mutations[329]. In a Phase 1 study for treatment-naive patients with NSCLC, best ORRs of 78% (7/9) were observed in patients treated with combination gefitinib and the PD-L1 inhibitor durvalumab as first-line treatment and of 80% (8/10) in those treated with the combination after gefitinib monotherapy[330].

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

Osimertinib

Assay findings association

EGFR
exon 19 deletion (T751_I759>N)

AREAS OF THERAPEUTIC USE

Osimertinib is an irreversible EGFR tyrosine kinase inhibitor (TKI) that is selective for EGFR TKI-sensitizing mutations and the EGFR T790M mutation. It is available in the EU in various treatment settings for patients with non-small cell lung cancer (NSCLC) whose tumors harbor EGFR T790M mutations or activating mutations, including EGFR exon 19 deletions and exon 21 L858R mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR TKI-sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non-small cell lung cancer[68,104,323,331-332]. Patients with untreated advanced NSCLC and EGFR exon 19 deletions or L858R mutations achieved an ORR of 80% and a median PFS of 21.4 and 14.4 months, respectively[104].

SUPPORTING DATA

The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first-line osimertinib significantly increased both median PFS (18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced NSCLC and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858)[104,333]. In the Phase 3 ADAURA study, patients with early Stage (IB/II/IIIA) EGFR-mutated NSCLC experienced longer PFSs on osimertinib compared to placebo in the adjuvant setting (not reached vs. 28.1 months; HR=0.21)[334]. A Phase 1 study reported that T790M-negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months[68]. A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR-mutated, T790M-negative NSCLC reported an ORR of 19% (4/19), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 1/2 trial of osimertinib in combination with bevacizumab for patients with untreated metastatic EGFR-mutated non-small cell lung cancer (NSCLC) reported an 80% (39/49) ORR, a 100% (6/6, 2 CRs) central nervous system response rate, median PFS of 19 months, and a 1-year PFS rate of 72%[335]. The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR-mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively[336].

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies listed in this report may not be complete and exhaustive and the therapeutic agents are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type.

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

NOTE Clinical trials are ordered by gene and prioritized in the following descending order: Pediatric trial qualification → Geographical proximity → Trial phase → Trial verification within last 2 months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. The clinical trials listed in this report may not be complete and exhaustive or may include trials for which the patient does not meet the clinical trial enrollment criteria. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov or local registries in your region.

GENE
CCND1

ALTERATION
amplification

RATIONALE
CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single-agent CDK4/6 inhibitors.

NCT04000529

PHASE 1

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

TARGETS
PD-1, SHP2, CDK6, CDK4

LOCATIONS: Barcelona (Spain), Koeln (Germany), Bruxelles (Belgium), Massachusetts, Chengdu (China), Hong Kong (Hong Kong), Singapore (Singapore), Chuo ku (Japan), Westmead (Australia)

NCT02664935

PHASE 2

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

TARGETS
FGFRs, mTORC1, mTORC2, CDK4, CDK6, ALK, AXL, MET, ROS1, TRKA, TRKC, MEK, AKTs, EGFR, PD-L1, DDR2, FLT3, KIT, PDGFRA, RET, TRKB, VEGFRs

LOCATIONS: Maidstone (United Kingdom), Colchester (United Kingdom), London (United Kingdom), Southampton (United Kingdom), Cambridge (United Kingdom), Oxford (United Kingdom), Exeter (United Kingdom), Bristol (United Kingdom), Leicester (United Kingdom), Cardiff (United Kingdom)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04553133

PHASE 2

PF-07104091 as a Single Agent and in Combination Therapy

TARGETS
Aromatase, CDK4, CDK6, CDK2

LOCATIONS: Massachusetts, Michigan, Texas

NCT02896335

PHASE 2

Palbociclib In Progressive Brain Metastases

TARGETS
CDK4, CDK6

LOCATIONS: Massachusetts

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO

LOCATIONS: Montreal (Canada), Ottawa (Canada), Kingston (Canada), Toronto (Canada), London (Canada), Saskatoon (Canada), Regina (Canada), Edmonton (Canada), Vancouver (Canada)

NCT03065062

PHASE 1

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

TARGETS
PI3K-alpha, PI3K-gamma, mTORC1, mTORC2, CDK4, CDK6

LOCATIONS: Massachusetts

NCT03454035

PHASE 1

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

TARGETS
MAPK3, MAPK1, CDK4, CDK6

LOCATIONS: North Carolina

NCT02897375

PHASE 1

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

TARGETS
CDK4, CDK6

LOCATIONS: Georgia

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE
CDK4

RATIONALE
CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.

ALTERATION
amplification - equivocal

NCT03099174

PHASE 1

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.

TARGETS
CDK4, CDK6, IGF-1, IGF-2, Aromatase, ER

LOCATIONS: Paris (France), Marseille (France), Barcelona (Spain), L'Hospitalet de Llobregat (Spain), Besançon (France), Madrid (Spain), Pozuelo de Alarcón (Spain), Malaga (Spain), Plerin Sur Mer (France), København Ø (Denmark)

NCT04000529

PHASE 1

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

TARGETS
PD-1, SHP2, CDK6, CDK4

LOCATIONS: Barcelona (Spain), Koeln (Germany), Bruxelles (Belgium), Massachusetts, Chengdu (China), Hong Kong (Hong Kong), Singapore (Singapore), Chuo ku (Japan), Westmead (Australia)

NCT02664935

PHASE 2

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

TARGETS
FGFRs, mTORC1, mTORC2, CDK4, CDK6, ALK, AXL, MET, ROS1, TRKA, TRKC, MEK, AKTs, EGFR, PD-L1, DDR2, FLT3, KIT, PDGFRA, RET, TRKB, VEGFRs

LOCATIONS: Maidstone (United Kingdom), Colchester (United Kingdom), London (United Kingdom), Southampton (United Kingdom), Cambridge (United Kingdom), Oxford (United Kingdom), Exeter (United Kingdom), Bristol (United Kingdom), Leicester (United Kingdom), Cardiff (United Kingdom)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT02693535

PHASE 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

TARGETS
VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, CDK4, CDK6, CSF1R, FLT3, KIT, RET, mTOR, EGFR, ERBB2, ERBB3, MEK, BRAF, SMO, DDR2, PARP, PD-1, CTLA-4, ERBB4

LOCATIONS: Maine

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

CLINICAL TRIALS

NCT03994796

PHASE 2

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

TARGETS
ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR

LOCATIONS: Massachusetts, Vermont, New Hampshire, New York, Connecticut, New Jersey

NCT04553133

PHASE 2

PF-07104091 as a Single Agent and in Combination Therapy

TARGETS
Aromatase, CDK4, CDK6, CDK2

LOCATIONS: Massachusetts, Michigan, Texas

NCT02896335

PHASE 2

Palbociclib In Progressive Brain Metastases

TARGETS
CDK4, CDK6

LOCATIONS: Massachusetts

NCT03310879

PHASE 2

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

TARGETS
CDK4, CDK6

LOCATIONS: Massachusetts

NCT03297606

PHASE 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

TARGETS
VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD-1, CTLA-4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO

LOCATIONS: Montreal (Canada), Ottawa (Canada), Kingston (Canada), Toronto (Canada), London (Canada), Saskatoon (Canada), Regina (Canada), Edmonton (Canada), Vancouver (Canada)

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

GENE
EGFR

ALTERATION
exon 19 deletion (T751_I759>N)

RATIONALE
EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.

NCT04487080

PHASE 3

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

TARGETS
MET, EGFR

LOCATIONS: Catania (Italy), Napoli (Italy), Avellino (Italy), Meldola (Italy), Ravenna (Italy), Rozzano (Italy), Milano (Italy), Marseille Cedex 20 (France), Monza (Italy), Orbassano (Italy)

NCT04811001

PHASE 2

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

TARGETS
EGFR, ERBB2, ERBB4

LOCATIONS: Napoli (Italy), Roma (Italy), Padova (Italy), Novara (Italy)

NCT04077463

PHASE 1

A Study of Lazertinib as Monotherapy or in Combination With JNJ-61186372 in Japanese Participants With Advanced Non-small Cell Lung Cancer

TARGETS
EGFR, MET

LOCATIONS: Napoli (Italy), Ravenna (Italy), Marseille (France), Milano (Italy), Barcelona (Spain), Lyon Cedex 8 (France), Gauting (Germany), Stuttgart (Germany), Bordeaux (France), Poitiers (France)

NCT04248829

PHASE 3

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

TARGETS
EGFR

LOCATIONS: Patras (Greece), Larissa (Greece), Thessaloníki (Greece), Athens (Greece), Kragujevac (Serbia), Niš (Serbia), Belgrade (Serbia), Sremska Kamenica (Serbia), Székesfehérvár (Hungary), Tatabánya (Hungary)

NCT03521154

PHASE 3

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

TARGETS
EGFR

LOCATIONS: Pécs (Hungary), Barcelona (Spain), Székesfehérvár (Hungary), Törökbálint (Hungary), Budapest (Hungary), Valencia (Spain), Izmir (Turkey), Gyöngyös - Mátraháza (Hungary), Istanbul (Turkey), San Sebastián (Spain)

NCT04035486

PHASE 3

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

TARGETS
EGFR

LOCATIONS: Montpellier (France), Lyon (France), Banska Bystrica (Slovakia), Olomouc (Czechia), Praha (Czechia), Praha 5 (Czechia), Poprad (Slovakia), Kosice (Slovakia), Ostrava - Vitkovice (Czechia), Bordeaux Cedex (France)

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

CLINICAL TRIALS

NCT04413201

PHASE 4

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

TARGETS
EGFR, ERBB2, ERBB4

LOCATIONS: Immenstadt (Germany), Konstanz (Germany), Regensburg (Germany), Löwenstein (Germany), Hamm (Germany), Berlin (Germany), Bremen (Germany), Hamburg (Germany)

NCT03865511

PHASE 2

MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib

TARGETS
EGFR

LOCATIONS: Toulon (France), Cholet (France), Le Mans (France), Nantes (France)

NCT04233021

PHASE 2

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

TARGETS
EGFR

LOCATIONS: Toulon (France), Marseille (France), Aix-en-Provence (France), Avignon (France), Montpellier (France), Grenoble (France), Pierre-Bénite (France), Lyon (France), Villefranche-sur-Saône (France), Toulouse (France)

NCT04619004

PHASE 2

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

TARGETS
ERBB3

LOCATIONS: Rozzano (Italy), Milano (Italy), Orbassano (Italy), Grenoble (France), Barcelona (Spain), Lyon (France), Toulouse (France), Zaragoza (Spain), Dresden (Germany), Villejuif (France)

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ATR
E471Q

CREBBP
P323R

EGFR
amplification

FAM123B
F127L

IKZF1
amplification

IRS2
A701_V702insAA

MED12
Q2119_Q2120insHQQQ

RAC1
amplification

SDHA
T273I

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

APPENDIX Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER GENOMIC SIGNATURES

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes. Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: The association of a therapy with a genomic alteration or signature does not necessarily indicate pharmacologic effectiveness (or lack thereof); no association of a therapy with a genomic alteration or signature does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness).

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Genomic signatures and gene alterations detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each genomic signature or gene alteration. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X,

"MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively

determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

The median exon coverage for this sample is 943x

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Warth A, et al. Virchows Arch. (2016) pmid: 26637197
7. Ninomiya H, et al. Br. J. Cancer (2006) pmid: 16641899
8. Vanderwalde A, et al. Cancer Med (2018) pmid: 29436178
9. Zang YS, et al. Cancer Med (2019) pmid: 31270941
10. Dudley JC, et al. Clin. Cancer Res. (2016) pmid: 26880610
11. Takamochi K, et al. Lung Cancer (2017) pmid: 28676214
12. Pylkkänen L, et al. Environ. Mol. Mutagen. (1997) pmid: 9329646
13. Gonzalez R, et al. Ann. Oncol. (2000) pmid: 11061602
14. Chen XQ, et al. Nat. Med. (1996) pmid: 8782463
15. Merlo A, et al. Cancer Res. (1994) pmid: 8174113
16. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
17. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
18. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
19. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
20. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
21. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
22. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
23. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
24. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
25. Cristescu R, et al. Science (2018) pmid: 30309915
26. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
27. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
28. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
29. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
30. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
31. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
32. Rizvi NA, et al. Science (2015) pmid: 25765070
33. Colli LM, et al. Cancer Res. (2016) pmid: 27197178
34. Wang VE, et al. J Immunother Cancer (2017) pmid: 28923100
35. Carbone DP, et al. N. Engl. J. Med. (2017) pmid: 28636851
36. Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640
37. Forde PM, et al. N. Engl. J. Med. (2018) pmid: 29658848
38. Miao D, et al. Nat. Genet. (2018) pmid: 30150660
39. Chae YK, et al. Clin Lung Cancer (2019) pmid: 30425022
40. Paz-Ares et al., 2019; ESMO Abstract LBA80
41. Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796
42. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
43. Spigel et al., 2016; ASCO Abstract 9017
44. Xiao D, et al. Oncotarget (2016) pmid: 27009843
45. Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269
46. Govindan R, et al. Cell (2012) pmid: 22980976
47. Ding L, et al. Nature (2008) pmid: 18948947
48. Imielinski M, et al. Cell (2012) pmid: 22980975
49. Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028
50. Stein et al., 2019; DOI: 10.1200/PO.18.00376
51. Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500
52. Yu H, et al. J Thorac Oncol (2019) pmid: 30253973
53. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
54. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
55. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
56. Johnson BE, et al. Science (2014) pmid: 24336570
57. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
58. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
59. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
60. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
61. Nature (2012) pmid: 22810696
62. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
63. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
64. Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168
65. Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064
66. Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960
67. Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379
68. Jänne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549
69. Hong MH, et al. Cancer (2020) pmid: 32749686
70. Kim HS, et al. Oncotarget (2015) pmid: 26462025
71. Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851
72. Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840
73. Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047
74. Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886
75. Leighl et al., 2021; ESMO Abstract 1192MO
76. Cho et al., 2020; ESMO Abstract 1258O
77. Bauml et al., 2021; ASCO Abstract 9006
78. Shu et al., 2021; ESMO Abstract 1193MO
79. Janne et al., 2021; ASCO Abstract 9007
80. Ahn MJ, et al. Lancet Respir Med (2017) pmid: 29056570
81. Yang Z, et al. Sci Transl Med (2016) pmid: 27928026
82. Ahn MJ, et al. Lancet Oncol (2019) pmid: 31587882
83. Socinski MA, et al. N. Engl. J. Med. (2018) pmid: 29863955
84. Vallee A, et al. Int. J. Oncol. (2013) pmid: 23934203
85. Nature (2014) pmid: 25079552
86. Nature (2012) pmid: 22960745
87. Watzka SB, et al. Eur J Cardiothorac Surg (2010) pmid: 20353893
88. Liang Z, et al. BMC Cancer (2010) pmid: 20637128
89. Grob TJ, et al. Lung Cancer (2013) pmid: 23238037
90. Park S, et al. Histol. Histopathol. (2012) pmid: 22207554
91. Dobashi Y, et al. Hum. Pathol. (2011) pmid: 21040950
92. Ludovini V, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23314677
93. Skrzypski M, et al. Clin Lung Cancer (2013) pmid: 23870818
94. Kim SH, et al. Histol. Histopathol. (2012) pmid: 22419022
95. Lee JS, et al. Ann. Surg. Oncol. (2013) pmid: 23525704
96. Oakley GJ, et al. J Thorac Oncol (2011) pmid: 21587084
97. Marks JL, et al. J Thorac Oncol (2008) pmid: 18303429
98. Izar B, et al. Ann. Thorac. Surg. (2013) pmid: 23932319
99. Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605
100. Lynch TJ, et al. N. Engl. J. Med. (2004) pmid: 15118073
101. Paez JG, et al. Science (2004) pmid: 15118125
102. Pao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2004) pmid: 15329413
103. Yang JC, et al. Lancet Oncol. (2015) pmid: 25589191
104. Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359
105. Wu YL, et al. Lancet Oncol. (2017) pmid: 28958502
106. Gilmer TM, et al. Cancer Res. (2008) pmid: 18199554
107. Foster SA, et al. Cancer Cell (2016) pmid: 26996308
108. Morschhauser F, et al. Haematologica (2020) pmid: 32381571
109. Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362
110. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
111. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
112. Patnaik A, et al. Cancer Discov (2016) pmid: 27217383
113. Leonard JP, et al. Blood (2012) pmid: 22383795
114. Dickler MN, et al. Clin. Cancer Res. (2017) pmid: 28533223
115. Clark et al., 2019; AACR Abstract LB-010/2
116. Peguero et al., 2016; ASCO Abstract 2528
117. Chen Y, et al. Front Immunol (2020) pmid: 32903763
118. Litchfield K, et al. Cell (2021) pmid: 33508232
119. Reissmann PT, et al. J. Cancer Res. Clin. Oncol. (1999) pmid: 10190311
120. Marchetti A, et al. Int. J. Cancer (1998) pmid: 9462706
121. Sun W, et al. J Biomed Res (2013) pmid: 23720678
122. Gautschi O, et al. Lung Cancer (2007) pmid: 17070615
123. Elsheikh S, et al. Breast Cancer Res. Treat. (2008) pmid: 17653856
124. Fu M, et al. Endocrinology (2004) pmid: 15331580
125. Takahashi-Yanaga F, et al. Cell. Signal. (2008) pmid: 18023328
126. Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312
127. Dickson et al., 2019; ASCO Abstract 11004
128. Dickson MA, et al. JAMA Oncol (2016) pmid: 27124835
129. Campbell JD, et al. Nat. Genet. (2016) pmid: 27158780
130. Wikman H, et al. Genes Chromosomes Cancer (2005) pmid: 15543620
131. Borczuk AC, et al. Am. J. Pathol. (2003) pmid: 14578194
132. Wu A, et al. J Transl Med (2011) pmid: 21477379
133. Puyol M, et al. Cancer Cell (2010) pmid: 20609353
134. Choi YJ, et al. Oncogene (2014) pmid: 23644662
135. Cell (1995) pmid: 7736585
136. Musgrove EA, et al. Nat. Rev. Cancer (2011) pmid: 21734724
137. Rao SK, et al. J. Neurooncol. (2010) pmid: 19609742
138. Chung L, et al. Am. J. Surg. Pathol. (2009) pmid: 19574885
139. Ragazzini P, et al. Histol. Histopathol. (2004) pmid: 15024701
140. Dujardin F, et al. Mod. Pathol. (2011) pmid: 21336260
141. Zhang K, et al. Cancer Res. (2013) pmid: 23393200
142. Horvai AE, et al. Mod. Pathol. (2009) pmid: 19734852
143. Guagnano V, et al. Cancer Discov (2012) pmid: 23002168
144. Hatlen MA, et al. Cancer Discov (2019) pmid: 31575540
145. Hagel M, et al. Cancer Discov (2015) pmid: 25776529
146. Kim RD, et al. Cancer Discov (2019) pmid: 31575541
147. Chan et al., 2017; AACR Abstract CT106/24
148. Kaibori M, et al. Oncotarget (2016) pmid: 27384874
149. Dumbrava EI, et al. JCO Precis Oncol (2018) pmid: 31123723
150. Packer LM, et al. Cancer Discov (2015) pmid: 25847957
151. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
152. Gao J, et al. Sci Signal (2013) pmid: 23550210
153. Desnoyers LR, et al. Oncogene (2008) pmid: 17599042
154. Sawey ET, et al. Cancer Cell (2011) pmid: 21397858
155. Miura S, et al. BMC Cancer (2012) pmid: 22309595
156. Feng S, et al. Cancer Res. (2013) pmid: 23440425
157. Nagamatsu H, et al. Prostate (2015) pmid: 25854696
158. Xie MH, et al. Cytokine (1999) pmid: 10525310

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

159. Int. J. Oncol. (2002) pmid: 12429977
160. Kan Z, et al. Genome Res. (2013) pmid: 23788652
161. Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100
162. Tekin M, et al. Am. J. Hum. Genet. (2007) pmid: 17236138
163. Arao T, et al. Hepatology (2013) pmid: 22890726
164. Yamada T, et al. BMC Cancer (2015) pmid: 25885470
165. Kratochwil K, et al. Genes Dev. (2002) pmid: 12502739
166. Scherz PJ, et al. Science (2004) pmid: 15256670
167. Zaharieva BM, et al. J. Pathol. (2003) pmid: 14648664
168. Arai H, et al. Cancer Genet. Cytogenet. (2003) pmid: 14499691
169. Ribeiro IP, et al. Tumour Biol. (2014) pmid: 24477574
170. Schulze K, et al. Nat. Genet. (2015) pmid: 25822088
171. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
172. Robinson G, et al. Nature (2012) pmid: 22722829
173. Ho AS, et al. Nat. Genet. (2013) pmid: 23685749
174. Grasso CS, et al. Nature (2012) pmid: 22722839
175. Van der Meulen J, et al. Blood (2015) pmid: 25320243
176. Wang L, et al. Nat Commun (2013) pmid: 23792809
177. Kim JH, et al. Cancer Res. (2014) pmid: 24491801
178. Shen Y, et al. BMC Cancer (2012) pmid: 23057811
179. van Haaften G, et al. Nat. Genet. (2009) pmid: 19330029
180. Kumar A, et al. Nat. Med. (2016) pmid: 26928463
181. Bivona TG, et al. Nature (2011) pmid: 21430781
182. Giannikopoulos et al., 2014; ASCO Abstract 8083
183. Zhao Z, et al. Int. J. Mol. Med. (2014) pmid: 25215581
184. Geng P, et al. Medicine (Baltimore) (2015) pmid: 26252270
185. Zhang M, et al. Med. Sci. Monit. (2015) pmid: 26488500
186. Weniger MA, et al. Semin. Cancer Biol. (2016) pmid: 27221964
187. Liu X, et al. Cancer Genet. Cytogenet. (2010) pmid: 20193848
188. Lake A, et al. Int. J. Cancer (2009) pmid: 19507254
189. Birnstiel ML, et al. Arch Biol (Liege) (1965) pmid: 5858823
190. Cabannes E, et al. Oncogene (1999) pmid: 10340377
191. Bredel M, et al. N. Engl. J. Med. (2011) pmid: 21175304
192. Patanè M, et al. Mol. Cancer (2013) pmid: 24330732
193. Zack TI, et al. Nat. Genet. (2013) pmid: 24071852
194. Beroukhim R, et al. Nature (2010) pmid: 20164920
195. Hsu DS, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19279207
196. Yang L, et al. J Zhejiang Univ Sci B (2012) pmid: 23125078
197. Landa I, et al. J. Clin. Invest. (2016) pmid: 26878173
198. Jiao Y, et al. J. Pathol. (2014) pmid: 24293293
199. Jones S, et al. Nat Commun (2014) pmid: 25233892
200. Nakamura N, et al. Mod. Pathol. (2002) pmid: 12379752
201. Moldvay J, et al. Pathol. Oncol. Res. (2004) pmid: 15188024
202. Gilbert-Sirieix M, et al. PLoS ONE (2011) pmid: 21814573
203. Robens J, et al. Am. J. Surg. Pathol. (2010) pmid: 21107096
204. Ni YB, et al. Histopathology (2014) pmid: 24111789
205. Tsai LH, et al. Oncogene (2014) pmid: 23995788
206. Tan D, et al. Hum. Pathol. (2003) pmid: 12827614
207. Haque AK, et al. Appl. Immunohistochem. Mol. Morphol. (2002) pmid: 12051626
208. Pelosi G, et al. Am. J. Surg. Pathol. (2001) pmid: 11224607
209. Yamaguchi T, et al. Cancer Cell (2013) pmid: 23763999
210. J. Biol. Chem. (2013) pmid: 23818522
211. Hamdan H, et al. Biochim. Biophys. Acta (1998) pmid: 9545595
212. Kwei KA, et al. Oncogene (2008) pmid: 18212743
213. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
214. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
215. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
216. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
217. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
218. Xu L, et al. Mol. Med. (2001) pmid: 11713371
219. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
220. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
221. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
222. Hajdenberg et al., 2012; ASCO Abstract e15010
223. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
224. Moore et al., 2019; ASCO Abstract 5513
225. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
226. Oza et al., 2015; ASCO Abstract 5506
227. Lee J, et al. Cancer Discov (2019) pmid: 31315834
228. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
229. Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188
230. Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953
231. Mohell N, et al. Cell Death Dis (2015) pmid: 26086967
232. Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933
233. Gourley et al., 2016; ASCO Abstract 5571
234. Kwok M, et al. Blood (2016) pmid: 26563132
235. Boudny M, et al. Haematologica (2019) pmid: 30975914
236. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704
237. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
238. Mogi A, et al. J. Biomed. Biotechnol. (2011) pmid: 21331359
239. Tekpli X, et al. Int. J. Cancer (2013) pmid: 23011884
240. Vignot S, et al. J. Clin. Oncol. (2013) pmid: 23630207
241. Maeng CH, et al. Anticancer Res. (2013) pmid: 24222160
242. Cortot AB, et al. Clin Lung Cancer (2014) pmid: 24169260
243. Itakura M, et al. Br. J. Cancer (2013) pmid: 23922113
244. Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262
245. Seo JS, et al. Genome Res. (2012) pmid: 22975805
246. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
247. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
248. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
249. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
250. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
251. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
252. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
253. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
254. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
255. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
256. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
257. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
258. Lalloo F, et al. Lancet (2003) pmid: 12672316
259. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
260. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
261. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
262. Xie M, et al. Nat. Med. (2014) pmid: 25326804
263. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
264. Severson EA, et al. Blood (2018) pmid: 29678827
265. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
266. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
267. Chabon JJ, et al. Nature (2020) pmid: 32269342
268. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
269. Wu YL, et al. Lancet Oncol. (2014) pmid: 24439929
270. Passaro et al., 2019; ELCC Abstract 1150
271. Audet et al., 2013; ASCO Abstract 6041
272. Lau SC, et al. Clin Lung Cancer (2019) pmid: 31178389
273. Paz-Ares L, et al. Ann. Oncol. (2017) pmid: 28426106
274. Thongprasert S, et al. Lung Cancer Manag (2019) pmid: 31807143
275. Januszewski et al., 2018; IASLC WCLC Abstract P1.13-17
276. Suzuki et al., 2018; IASLC WCLC Abstract P1.01-92
277. Chang et al., 2018; IASLC WCLC Abstract P1.01-11
278. Llinás-Quintero N, et al. Case Rep Oncol Med (2019) pmid: 31637072
279. Miller VA, et al. Lancet Oncol. (2012) pmid: 22452896
280. Chen X, et al. Lung Cancer (2013) pmid: 23664448
281. Katakami N, et al. J. Clin. Oncol. (2013) pmid: 23816963
282. Landi L, et al. Clin Lung Cancer (2014) pmid: 25242668
283. De Grève J, et al. Lung Cancer (2015) pmid: 25682316
284. Yang JC, et al. Lancet Oncol. (2015) pmid: 26051236
285. Horn L, et al. Lung Cancer (2017) pmid: 29110849
286. Yamamoto N, et al. Adv Ther (2020) pmid: 31863283
287. Soria JC, et al. Lancet Oncol. (2015) pmid: 26156651
288. Dziadziuszko R, et al. J Thorac Oncol (2019) pmid: 30825613
289. Lai WV, et al. Eur. J. Cancer (2019) pmid: 30685684
290. Greulich H, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22908275
291. Gow CH, et al. J Thorac Oncol (2015) pmid: 26134234
292. Mazières J, et al. Ann. Oncol. (2016) pmid: 26598547
293. Mazières J, et al. J. Clin. Oncol. (2013) pmid: 23610105
294. De Grève J, et al. Lung Cancer (2012) pmid: 22325357
295. Li BT, et al. Lung Cancer (2015) pmid: 26559459
296. Costa DB, et al. J Thorac Oncol (2016) pmid: 26964772
297. Yuan B, et al. Front Oncol (2020) pmid: 32477948
298. Fang W, et al. Oncologist (2019) pmid: 31748336
299. Schuler M, et al. Ann. Oncol. (2016) pmid: 26646759
300. Opsomer RJ, et al. Acta Urol Belg (1985) pmid: 2986437
301. Wu et al., 2018; WCLC abstract MA26.11
302. Ramalingam SS, et al. Ann. Oncol. (2016) pmid: 26768165
303. Yu HA, et al. Lung Cancer (2017) pmid: 29191595
304. Reckamp KL, et al. Cancer (2014) pmid: 24501009
305. Jänne PA, et al. Clin. Cancer Res. (2011) pmid: 21220471
306. van Geel RMJM, et al. Br. J. Cancer (2020) pmid: 32147669
307. Jänne PA, et al. J Thorac Oncol (2016) pmid: 26899759
308. Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771
309. Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613
310. Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888
311. Yang JJ, et al. Br. J. Cancer (2017) pmid: 28103612
312. Lee CK, et al. J. Natl. Cancer Inst. (2017) pmid: 28376144
313. Nakagawa K, et al. Lancet Oncol. (2019) pmid: 31591063
314. Stinchcombe TE, et al. JAMA Oncol (2019) pmid: 31393548
315. Truini A, et al. Clin. Cancer Res. (2019) pmid: 31182434
316. Shepherd FA, et al. N. Engl. J. Med. (2005) pmid: 16014882

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany

317. Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314
318. Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926
319. Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809
320. Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680
321. Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826
322. Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556
323. Wang J, et al. Int. J. Cancer (2019) pmid: 30255937
324. Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831
325. Yoshioka H, et al. Ann. Oncol. (2019) pmid: 31553438
326. Fukuoka M, et al. J. Clin. Oncol. (2011) pmid: 21670455
327. Noronha V, et al. J. Clin. Oncol. (2019) pmid: 31411950
328. Hosomi Y, et al. J. Clin. Oncol. (2020) pmid: 31682542
329. Sutiman N, et al. J Thorac Oncol (2017) pmid: 27908825
330. Gibbons DL, et al. J Thorac Oncol (2016) pmid: 27198414
331. Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755
332. Kim et al., 2021; DOI: 10.1200/PO.20.00296
333. Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012
334. Herbst et al., 2020; ASCO Abstract LBA5
335. Yu HA, et al. JAMA Oncol (2020) pmid: 32463456
336. Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298

Electronically signed by Chelsea Marcus, M.D. |
Roche Customer Care: +49 7624 14 2098 or europe.foundationmedicine@roche.com

Sample Analysis: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany
Sample Preparation: Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany